Seelos Therapeutics (SEEL.Q) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on CNS and rare disorders, advancing late-stage therapeutic candidates with proven mechanisms of action targeting large unmet medical needs.

• Lead programs include SLS-002 (intranasal racemic ketamine for acute suicidal ideation in MDD) and SLS-005 (IV trehalose for ALS and SCA), both in advanced clinical development.

• Pipeline includes preclinical and clinical assets for Huntington's, Alzheimer's, Parkinson's, and Sanfilippo Syndrome, with a strategy to pursue expedited regulatory pathways.

• Recent strategic focus on mental health and cost reduction, including a 33% workforce reduction and reduced working hours to extend cash runway.

Financial performance and metrics

• Net loss for 2023 was $37.9 million, with a net loss per share of $61.84 (post-reverse split); Q1 2024 net loss was $2.7 million, or $1.64 per share.

• Cash and cash equivalents as of March 31, 2024, were approximately $0.5 million; outstanding principal on convertible note was $12.2 million as of June 14, 2024.

• Company does not expect to meet minimum cash balance covenants without additional financing, risking default on debt.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling stockholders; may receive cash proceeds from warrant exercises at $2.21 per share.

• Any proceeds from warrant exercises will be used for general corporate purposes, advancing product candidates, and servicing or repaying debt.